ShareCompartir
Volume 17, Number 4—April 2011
Dispatch
High Rates of Staphylococcus aureus USA400 Infection, Northern Canada
George R. Golding, Paul N. Levett, Ryan R. McDonald, James Irvine, Brian Quinn, Mandiangu Nsungu, Shirley Woods, Mohammad Khan, Marianna Ofner-Agostini, Michael R. Mulvey
, and the Northern Antibiotic Resistance Partnership
, and the Northern Antibiotic Resistance Partnership
Table 1
Broth microdilution antimicrobial susceptibilities of select MRSA and MSSA isolates, northern Canada, 2006–2008*
| Antimicrobial drug | MRSA isolates, n = 379 |
MSSA isolates, n = 286 |
p value | OR (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % R | MIC range | MIC50 | MIC90 | % R | MIC range | MIC50 | MIC90 | ||||
| Clindamycin | 4.2 | <0.25–>8 | <0.25 | <0.25 | 27.3 | <0.25–>8 | <0.25 | <0.25 | <0.001 | 0.12 (0.06–0.21) | |
| Erythromycin | 5.5 | <0.25–>8 | 1 | 2 | 28.0 | 0.5–>8 | 2 | >8 | <0.001 | 0.15 (0.09–0.26) | |
| Vancomycin | 0 | <0.25–2 | 1 | 1 | 0 | 0.5–2 | 1 | 1 | NS | – | |
| SXT | 0 | <0.25–2 | <0.25 | <0.25 | 0 | <0.25–2 | <0.25 | <0.25 | NS | – | |
| Tetracycline | 0.3 | <2–>16 | <2 | <2 | 0 | <2 | <2 | <2 | NS | – | |
| Ciprofloxacin | 2.4 | <0.12–>8 | 0.5 | 0.5 | 1.7 | 0.25–>8 | 0.5 | 0.5 | NS | – | |
| Rifampin | 0 | <0.25 | <0.25 | <0.25 | 0 | <0.25 | <0.25 | <0.25 | NS | – | |
| Fusidic acid | 2.1 | <0.06–>8 | 0.12 | 0.25 | 7.7 | <0.06–>8 | 0.25 | 0.5 | 0.001 | 0.26 (0.1–0.62) | |
| Linezolid | 0 | 0.5–4 | 2 | 4 | 0 | 1–4 | 4 | 4 | NS | – | |
| Gentamicin | 1.6 | <0.5–>16 | <0.5 | <0.5 | 8.0 | <0.5–>16 | <0.5 | 1 | <0.001 | 0.18 (0.07–0.48) | |
| Mupirocin | 86.5 | <0.12–>128 | >128 | >128 | 26.9 | <0.12–>128 | 0.5 | >128 | <0.001 | 17.46 (11.56–26.43) | |
| Synercid | 0 | <0.25–0.5 | <0.25 | 0.5 | 0 | <0.25–1 | 0.5 | 0.5 | NS | – | |
| Nitrofurantoin | 0 | <32 | <32 | <32 | 0 | <32 | <32 | <32 | NS | – | |
*Values are mg/mL except as indicated. MRSA, methicilllin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; R, resistant; OR, odds ratio; CI, confidence interval; MIC50, 50% minimum inhibitory concentration; MIC90, 90% inhibitory concentration; SXT, sulfamethoxazole/trimethoprim; NS, not significant.
1Members of the Northern Antibiotic Resistance Partnership are listed at the end of this article.
- Page created: July 25, 2011
- Page last updated: July 25, 2011
- Page last reviewed: July 25, 2011
- Centers for Disease Control and Prevention,
-
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)